No, sweating is not listed as a direct adverse effect in the Summary of Product Characteristics or MHRA prescribing information for Ozempic (semaglutide)
The SUSTAIN-6 trial, which included over 3,000 participants with type 2 diabetes at high cardiovascular risk, showed that Ozempic reduced the risk of major adverse cardiovascular events compared to placebo
The Anxiolytic Neuropeptide Redefining Stress and Cognitive Research RESEARCH DISCLAIMERThis article reviews published scientific literature for educational purposes only
Duan N, Zhang Y-H, Wang W-M, Wang X
Massachusetts Medicaid: nominal copay for covered T2D use
Noticeable changes in weight-related outcomes may occur over 812 weeks, with continued improvement over time.